Rep. Julie Johnson Sells Off Shares of DaVita Inc. (NYSE:DVA)

Posted by Defense World Staff on Oct 9th, 2025

Representative Julie Johnson (D-Texas) recently sold shares of DaVita Inc. (NYSE:DVA). In a filing disclosed on October 07th, the Representative disclosed that they had sold between $1,001 and $15,000 in DaVita stock on September 25th. The trade occurred in the Representative’s “MERRILL LYNCH LONG TERM GROWTH” account.

Representative Julie Johnson also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of Ameren (NYSE:AEE) on 9/25/2025.
Sold $1,001 – $15,000 in shares of WEC Energy Group (NYSE:WEC) on 9/25/2025.
Sold $1,001 – $15,000 in shares of Equinix (NASDAQ:EQIX) on 9/25/2025.
Sold $1,001 – $15,000 in shares of A. O. Smith (NYSE:AOS) on 9/25/2025.
Sold $1,001 – $15,000 in shares of Honeywell International (NASDAQ:HON) on 9/25/2025.
Sold $1,001 – $15,000 in shares of McCormick & Company, Incorporated (NYSE:MKC) on 9/25/2025.
Sold $1,001 – $15,000 in shares of Monster Beverage (NASDAQ:MNST) on 9/25/2025.
Sold $1,001 – $15,000 in shares of Molson Coors Beverage (NYSE:TAP) on 9/25/2025.
Sold $1,001 – $15,000 in shares of LyondellBasell Industries (NYSE:LYB) on 9/25/2025.
Sold $1,001 – $15,000 in shares of United Dominion Realty Trust (NYSE:UDR) on 9/25/2025.

DaVita Stock Performance

Shares of DVA stock opened at $127.93 on Thursday. The stock’s 50-day simple moving average is $133.83 and its 200-day simple moving average is $139.68. The firm has a market capitalization of $9.15 billion, a PE ratio of 12.58, a P/E/G ratio of 0.94 and a beta of 1.13. DaVita Inc. has a fifty-two week low of $126.07 and a fifty-two week high of $179.60.

DaVita (NYSE:DVA – Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $2.95 earnings per share for the quarter, beating analysts’ consensus estimates of $2.70 by $0.25. DaVita had a return on equity of 369.39% and a net margin of 6.35%.The business had revenue of $3.38 billion for the quarter, compared to analyst estimates of $3.36 billion. During the same period in the prior year, the company earned $2.00 earnings per share. The company’s revenue was up 6.1% on a year-over-year basis. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. Sell-side analysts forecast that DaVita Inc. will post 10.76 earnings per share for the current year.

Hedge Funds Weigh In On DaVita

Several institutional investors have recently made changes to their positions in DVA. Wealth Enhancement Advisory Services LLC increased its holdings in DaVita by 2.0% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 3,551 shares of the company’s stock worth $531,000 after acquiring an additional 69 shares in the last quarter. Wedmont Private Capital increased its holdings in DaVita by 17.8% in the 1st quarter. Wedmont Private Capital now owns 2,095 shares of the company’s stock worth $326,000 after acquiring an additional 317 shares in the last quarter. UMB Bank n.a. increased its holdings in DaVita by 65.5% in the 1st quarter. UMB Bank n.a. now owns 192 shares of the company’s stock worth $29,000 after acquiring an additional 76 shares in the last quarter. City Holding Co. increased its holdings in DaVita by 2.9% in the 1st quarter. City Holding Co. now owns 4,510 shares of the company’s stock worth $690,000 after acquiring an additional 129 shares in the last quarter. Finally, Farther Finance Advisors LLC increased its holdings in DaVita by 199.7% in the 1st quarter. Farther Finance Advisors LLC now owns 1,070 shares of the company’s stock worth $163,000 after acquiring an additional 713 shares in the last quarter. 90.12% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other DaVita news, insider James O. Hearty sold 2,351 shares of DaVita stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $150.00, for a total transaction of $352,650.00. Following the sale, the insider owned 26,038 shares of the company’s stock, valued at $3,905,700. The trade was a 8.28% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 1.50% of the company’s stock.

Wall Street Analyst Weigh In

DVA has been the subject of a number of recent research reports. Weiss Ratings reissued a “hold (c+)” rating on shares of DaVita in a research report on Wednesday. Wall Street Zen raised shares of DaVita from a “hold” rating to a “buy” rating in a research report on Saturday, September 13th. Barclays reduced their price target on shares of DaVita from $169.00 to $160.00 and set an “equal weight” rating for the company in a research report on Thursday, August 7th. Bank of America reduced their price target on shares of DaVita from $145.00 to $140.00 and set an “underperform” rating for the company in a research report on Wednesday, September 10th. Finally, Truist Financial set a $148.00 price target on shares of DaVita in a research report on Friday, August 8th. Four investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Reduce” and a consensus price target of $158.00.

Check Out Our Latest Stock Report on DVA

About Representative Johnson

Julie Johnson (Democratic Party) is a member of the U.S. House, representing Texas’ 32nd Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

Johnson (Democratic Party) ran for election to the U.S. House to represent Texas’ 32nd Congressional District. She won in the general election on November 5, 2024.

Julie Johnson earned a B.A. in history and government from the University of Texas at Austin in 1987 and a J.D. from the University of Houston Law Center in 1991. Johnson’s career experience includes working as an attorney.

About DaVita

(Get Free Report)

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.